AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Editas Medicine: HC Wainwright Raises PT to $5 from $4 on Buy Rating
ByAinvest
Friday, Sep 5, 2025 7:18 am ET1min read
Editas Medicine: HC Wainwright Raises PT to $5 from $4 on Buy Rating
HC Wainwright & Co. has raised its price target for Editas Medicine (EDIT) to $5.00 from $4.00, maintaining a "Buy" rating on the stock [1]. This adjustment marks a 25% increase in the target price, reflecting a more optimistic outlook on the stock's potential performance.Editas Medicine is a clinical-stage genome editing company focused on developing transformative genomic medicines to treat a broad range of serious diseases. The company's proprietary gene editing platform is based on CRISPR technology, which uses a protein-RNA complex to recognize and edit specific DNA sequences [2].
The latest earnings report from Editas Medicine indicated a loss of $0.63 per share, missing analysts' estimates, but exceeding revenue expectations with $3.58 million reported [3]. Despite the earnings miss, the company's strong cash position and operational runway into the second quarter of 2027 suggest that it is well-positioned for future growth [4].
The consensus recommendation from brokerage firms is currently "Hold," with an average 12-month price target of $5.10 [3]. However, the recent price target increase by HC Wainwright indicates a shift in sentiment among analysts.
Editas Medicine's lead program, reni-cel, is an experimental ex vivo gene-edited medicine to treat sickle cell disease (SCD) and transfusion-dependent beta-thalassemia [2]. The company is also developing EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis.
The stock has shown volatility in recent months, trading between $0.91 and $4.12 over the past year. Institutional investors own 71.90% of the company's stock [3].
References:
[1] https://www.gurufocus.com/news/3092849/editas-medicine-edit-sees-analyst-price-target-raised-by-wells-fargo-edit-stock-news
[2] https://www.marketscreener.com/news/editas-medicine-picks-edit-401-gene-editing-drug-as-lead-in-vivo-development-candidate-ce7c50d3de8bf123
[3] https://www.marketbeat.com/instant-alerts/editas-medicine-inc-nasdaqedit-receives-consensus-recommendation-of-hold-from-analysts-2025-08-31/
[4] https://www.morningstar.com/news/globe-newswire/9521261/editas-medicine-nominates-edit-401-an-ldlr-targeted-medicine-as-lead-in-vivo-development-candidate
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet